Daniel J. Nevrivy, Ph.D.

Dr. Nevrivy represents clients who are on the cutting edge in the life sciences. His practice includes preparing and prosecuting patent applications in the fields of biotechnology and pharmaceuticals, in particular stem cells and regenerative medicine, diagnostics, genomics, antibodies, inflammation, cancer, menopausal diseases, fertility, vaccines, pharmaceutical formulation and drug delivery technologies, and therapeutic methods of treatment. He also counsels clients regarding intellectual property strategies and patent portfolio management. He has extensive experience helping clients maximize the value of their intellectual property. His clients include investor groups, entrepreneurs, startup firms, leading research universities, and emerging and established corporations.

Dr. Nevrivy's practice further encompasses conducting freedom to operate, due diligence, patentability, invalidity and noninfringement investigations. In particular, he has significant experience helping companies navigate the complex patent issues associated with the development of pharmaceutical products.

Prior to entering law, Dr. Nevrivy conducted scientific research in the fields of molecular and cellular biology and molecular pharmacology. He investigated the role of retinoids and their effects on pluripotent embryonal carcinoma cells and he identified and characterized the function of a retinoic acid induced gene from these cells. In addition, he worked on projects relating to mechanisms of transcriptional activation and repression mediated by members of the steroid/thyroid hormone receptor superfamily, which include the retinoic acid receptors (RARs) and peroxisome proliferator-activated receptors (PPARs), among many others.

Dr. Nevrivy has a decade of experience in intellectual property law. Before starting the firm, he was with an intellectual property specialty firm in Washington, D.C. Dr. Nevrivy's recent interviews and publications include:

"Implementation of European Court Decision to Ban hESC Patents Depends on National Patent Offices" Genetic Engineering & Biotechnology News

"Asia's Emerging Markets Catching Up to the U.S. and Europe in Terms of Innovation" Genetic Engineering & Biotechnology News

"The Myriad Genetics Ruling - was the global biotech industry gutted? "National Public Radio (Tech Nation), to listen click here.

"China gets serious about biotech," FierceBiotech

"Alkermes To Put Its Long-Acting Stamp On Trusted Blockbusters, Starting With Abilify," "The Pink Sheet," Elsevier, February 2010

"Saving Roman" - a video about the childhood cancer neuroblastoma produced by the Biotechnology Industry Organization (BIO) and showcased at the 2009 BIO International Convention keynote luncheon (see the YouTube video below, around the 4:00 minute mark)

"Expert in Patent Law in the Life Sciences Provides Insight on Today's Market and the Outlook for the Future of Biotech and Pharma Companies," Life Science Executive Exchange

"Restoring Science to its Rightful Place in America," IPLaw360

"Does the U.S. biotech industry deserve a bailout?" FiercePharma and FierceBiotech

Contact Information

Phone: 202-247-6015
email: dnevrivy@nevrivylaw.com

Admissions

District of Columbia
U.S. Patent and Trademark Office

Education

J.D. George Mason University
Ph.D. Molecular and Cellular Biology, Oregon State University
B.S. Biology and B.A. Chemistry, Trinity University (TX)

Associations & Memberships

Association of University Technology Managers (AUTM)
District of Columbia Bar Association
Technology Council of Maryland
MdBio

Dr. Nevrivy's technical publications include:

Nevrivy et al. Interaction of GRASP, a protein encoded by a novel retinoic acid-induced gene, with members of the cytohesin family of guanine nucleotide exchange factors. J Biol Chem 275(22):16827-36 (2000)

Avram et al. Isolation of a novel family of C(2)H(2) zinc finger proteins implicated in transcriptional repression mediated by chicken ovalbumin upstream promoter transcription factor (COUP-TF) orphan nuclear receptors. J Biol Chem 275(14):10315-22 (2000)

Dowell et al. Identification of nuclear receptor corepressor as a peroxisome proliferator-activated receptor alpha interacting protein. J Biol Chem 274(22):15901-7 (1999)

Avram et al. Heterodimeric interactions between chicken ovalbumin upstream promoter-transcription factor family members ARP1 and ear2. J Biol Chem 274(20):14331-6 (1999)

Dowell et al. p300 functions as a coactivator for the peroxisome proliferator-activated receptor alpha. J Biol Chem 272(52):33435-43 (1997)